- The Washington Times - Saturday, January 25, 2003

DAVOS, Switzerland (AP) Pharmacia Corp. announced yesterday that it would allow generic drug companies to manufacture cheap copies of its AIDS drug to sell in poor countries, a novel approach aimed at breaking the logjam over access to lifesaving medicines.
Pharmacia said it will work with the International Dispensary Association in Amsterdam to provide licenses and technological skills to generic companies to make its delavirdine, an anti-retroviral drug sold under the trade name Rescriptor.
AIDS activists praised the idea of using a nonprofit agency as an intermediary, even if the drug on offer is not in great demand. But they stressed that without billions more in aid from the West, the world's poorest countries wouldn't be able to afford even the generic versions.
"This is half of what's needed," said Dr. Amir Attaran of the Center for International Development at Harvard University, who helped develop the model. "This helps solve the supply side, but there's no demand because these countries are deadly poor."
The plan was announced at the World Economic Forum by Pharmacia, which is being acquired by Pfizer Inc., and groups involved in trying to bridge the often wide gap between drug companies and activists.
The association, a 30-year-old organization that works to get generic drugs into developing countries, would monitor production quality and collect a 5 percent royalty to cover costs and fund research.
The generic companies could then sell the copies in 78 countries where annual per-capita income is less than $1,200 or the HIV infection rate is above 1 percent.
The plan is meant as an alternative to compulsory licensing, under which countries facing health crises seize patent rights and make drugs without the cooperation of the original maker.
"We think its a very innovative step in the right direction," said Richard Feachem, executive director of the Geneva-based Global Fund to Fight AIDS, Tuberculosis and Malaria.
Drugs would be sold at a "reasonable price and with assured quality," Mr. Feachem said.
Most important for Pharmacia and other drug companies that were being encouraged to consider following suit, the copies would be different in shape, color, packaging and name from the same medicine sold in the West. This would help customs officials prevent smugglers from bringing the cheap version back into developed countries.
"If low-cost products undermine the high-cost market, then the profit goes, then the research and development goes," Mr. Feachem said.
Daniel Berman, a spokesman for the Access to Essential Medicines campaign at Doctors Without Borders, called the model "really quite interesting."
He called on other drugs companies to follow suit and for a mandatory system if they refuse.

Copyright © 2019 The Washington Times, LLC. Click here for reprint permission.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide